Ishita Drugs & Industries Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 444125, "name": "Ishita Drugs", "stock_name": "Ishita Drugs", "full_name": "Ishita Drugs & Industries Ltd", "name_url": "stocks-analysis/ishita-drugs", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "72.20", "chg": -2.8, "chgp": "-3.73%", "dir": -1, "prev_price": "75.00", "mcapval": "22.00 Cr", "mcap": "Micro Cap", "scripcode": 524400, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE806D01016", "curr_date": "Aug 12, 01:00 PM", "curr_time": "13:27 PM", "last_traded_at": "Aug 12, 01:00 PM IST", "bse_nse_vol": "505 ", "exc_status": "Active", "traded_date": "Aug 12, 2026", "traded_date_str": "2026 08 12", "score": "", "scoreText": "", "Live": 1, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amidst Flat Financials and Bearish Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-downgraded-to-strong-sell-amidst-flat-financials-and-bearish-technicals-4146687", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/IshitaDrugsIndu_mojoScore_4146687.png", "date": "2026-08-11 08:26:01", "description": "Ishita Drugs & Industries Ltd has been downgraded from a Sell to a Strong Sell rating as of 10 August 2026, reflecting deteriorating fundamentals and technical indicators. The pharmaceutical micro-cap’s financial trend has shifted from negative to flat, valuation has moved from attractive to fair, and technical signals have turned mildly bearish. This comprehensive reassessment by MarketsMOJO underscores the challenges facing the company amid sluggish sales and subdued market performance." }, { "title": "Ishita Drugs Declines 1.20% Despite Technical Upgrade: 2 Key Valuation Shifts This Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-declines-120-despite-technical-upgrade-2-key-valuation-shifts-this-week-4143693", "imagepath": "", "date": "2026-08-08 17:19:37", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>3 Aug:</strong> Technical upgrade to Sell rating announced</p>\n <p><strong>4 Aug:</strong> Stock price rises 0.87% to ₹77.78 amid upgrade optimism</p>\n <p><strong>5 Aug:</strong> Valuation grade shifts from attractive to fair</p>\n <p><strong>7 Aug:</strong> Stock closes week lower at ₹74.37 (-1.20%) despite Sensex gains</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹75.27</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">₹74.37</di..." }, { "title": "Ishita Drugs & Industries Ltd: Valuation Shifts Signal Changing Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-changing-price-attractiveness-4136730", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/IshitaDrugsIndu_valuationdot_4136730.png", "date": "2026-08-05 08:01:18", "description": "Ishita Drugs & Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid a backdrop of mixed financial metrics and peer comparisons, prompting investors to reassess the stock’s price attractiveness relative to its historical and sector benchmarks." }, { "title": "Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals", "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4135748", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/IshitaDrugsIndu_mojoScore_4135748.png", "date": "2026-08-04 08:25:32", "description": "Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. The company’s technical outlook has improved to mildly bullish, prompting the revision, although fundamental weaknesses persist in profitability and debt servicing capacity." }, { "title": "Ishita Drugs Declines 7.90% Amid Strong Sell Downgrade and Valuation Shifts", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-declines-790-amid-strong-sell-downgrade-and-valuation-shifts-4051504", "imagepath": "", "date": "2026-06-13 13:12:44", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>8 June:</strong> Downgrade to Strong Sell rating amid valuation and financial concerns</p>\n <p><strong>10 June:</strong> Valuation metrics shift from fair to attractive, signalling renewed price appeal</p>\n <p><strong>12 June:</strong> Stock closes the week at ₹75.06, down 7.90% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹81.50</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">₹75.06</div><div class=\"stat-change negative\">-7.90%</div>..." }, { "title": "Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-renewed-price-attractiveness-4043147", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IshitaDrugsIndu_valuationdot_4043147.png", "date": "2026-06-10 08:00:42", "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing market headwinds and a recent downgrade in its overall mojo grade to Strong Sell. This recalibration in price-to-earnings and price-to-book value metrics invites a closer examination of the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector." }, { "title": "Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Valuation and Financial Concerns", "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-downgraded-to-strong-sell-amid-valuation-and-financial-concerns-4040432", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IshitaDrugsIndu_mojoScore_4040432.png", "date": "2026-06-09 08:28:14", "description": "Ishita Drugs & Industries Ltd has been downgraded from a Sell to a Strong Sell rating as of 8 June 2026, reflecting deteriorating fundamentals and valuation pressures. The pharmaceutical company’s Mojo Score has dropped to 23.0, signalling heightened risk for investors amid weak financial trends, stretched valuation metrics, and unfavourable technical indicators." }, { "title": "Ishita Drugs & Industries Ltd: Valuation Shift Signals Price Attractiveness Change", "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shift-signals-price-attractiveness-change-4032684", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/IshitaDrugsIndu_valuationdot_4032684.png", "date": "2026-06-03 08:00:26", "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a change in price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector. This article analyses the implications of these valuation changes, comparing key metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios against industry benchmarks and historical trends, providing investors with a comprehensive view of the stock’s current standing." }, { "title": "Are Ishita Drugs & Industries Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-ishita-drugs-industries-ltd-latest-results-good-or-bad-4024797", "imagepath": "", "date": "2026-05-31 19:20:43", "description": "Ishita Drugs & Industries Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported net sales of ₹3.06 crores, reflecting a sequential decline of 2.55% from the previous quarter and a substantial year-on-year decrease of 32.89%. This pattern of revenue contraction indicates a troubling trend, particularly given the erratic sales performance over recent quarters, which has seen fluctuations ranging from a high of ₹5.40 crores to the current low.\n\nOn the profit side, the net profit for the quarter was ₹0.18 crores, which represents a 12.50% increase compared to the previous quarter, although it is down 37.93% year-on-year. This improvement in net profit is largely attributed to a significant increase in other income, which raises questions about the sustainability of earnings derived from core operations.\n\nOperating margins have also come under pressure, declin..." } ], "total": 127, "sid": "444125", "stock_news_url": "https://www.marketsmojo.com/news/ishita-drugs-industries-444125" }, "announcements": [ { "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On 08Th August 2026", "datetime": "08-Aug-2026", "details": "Outcome of the Board meeting held on 08th August 2026.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Change in Management", "datetime": "08-Aug-2026", "details": "Re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non -executive Non- Inependent Director of the Company post attaining the age of 75 years.", "source": "BSE" }, { "caption": "Outcome Of Board Meeting Held On 08H August 2026", "datetime": "08-Aug-2026", "details": "Unaudited Financial Results of the Compmany for the quarter ended 30th June 2026 along with limited review report issued by statutory auditor.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

3 Aug: Technical upgrade to Sell rating announced

4 Aug: Stock price rises 0.87% to ₹77.78 amid upgrade optimism

5 Aug: Valuation grade shifts from attractive to fair

7 Aug: Stock closes week lower at ₹74.37 (-1.20%) despite Sensex gains

Week Open

₹75.27

Week Close

₹74.37Read full news article

Ishita Drugs & Industries Ltd: Valuation Shifts Signal Changing Price Attractiveness

2026-08-05 08:01:18

Ishita Drugs & Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid a backdrop of mixed financial metrics and peer comparisons, prompting investors to reassess the stock’s price attractiveness relative to its historical and sector benchmarks.

Read full news article

Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-08-04 08:25:32

Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. The company’s technical outlook has improved to mildly bullish, prompting the revision, although fundamental weaknesses persist in profitability and debt servicing capacity.

Read full news article

Ishita Drugs Declines 7.90% Amid Strong Sell Downgrade and Valuation Shifts

2026-06-13 13:12:44

Key Events This Week

8 June: Downgrade to Strong Sell rating amid valuation and financial concerns

10 June: Valuation metrics shift from fair to attractive, signalling renewed price appeal

12 June: Stock closes the week at ₹75.06, down 7.90% for the week

Read full news article

Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-06-10 08:00:42

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing market headwinds and a recent downgrade in its overall mojo grade to Strong Sell. This recalibration in price-to-earnings and price-to-book value metrics invites a closer examination of the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Valuation and Financial Concerns

2026-06-09 08:28:14

Ishita Drugs & Industries Ltd has been downgraded from a Sell to a Strong Sell rating as of 8 June 2026, reflecting deteriorating fundamentals and valuation pressures. The pharmaceutical company’s Mojo Score has dropped to 23.0, signalling heightened risk for investors amid weak financial trends, stretched valuation metrics, and unfavourable technical indicators.

Read full news article

Ishita Drugs & Industries Ltd: Valuation Shift Signals Price Attractiveness Change

2026-06-03 08:00:26

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a change in price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector. This article analyses the implications of these valuation changes, comparing key metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios against industry benchmarks and historical trends, providing investors with a comprehensive view of the stock’s current standing.

Read full news article

Are Ishita Drugs & Industries Ltd latest results good or bad?

2026-05-31 19:20:43

Ishita Drugs & Industries Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported net sales of ₹3.06 crores, reflecting a sequential decline of 2.55% from the previous quarter and a substantial year-on-year decrease of 32.89%. This pattern of revenue contraction indicates a troubling trend, particularly given the erratic sales performance over recent quarters, which has seen fluctuations ranging from a high of ₹5.40 crores to the current low. On the profit side, the net profit for the quarter was ₹0.18 crores, which represents a 12.50% increase compared to the previous quarter, although it is down 37.93% year-on-year. This improvement in net profit is largely attributed to a significant increase in other income, which raises questions about the sustainability of earnings derived from core operations. Operating margins have also come under pressure, declin...

Read full news article

View All News